STOCK TITAN

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences clinical trial

I-Mab (NASDAQ: IMAB) announced it will present Phase 1 optimized dose estimation data for givastomig (TJ033721/ABL111) at SITC 2024. The presentation focuses on this novel first-in-class Claudin18.2 and 4-1BB bispecific antibody for cancer treatment. The poster presentation, numbered 1474, will take place on November 9, 2024, at the George R. Brown Convention Center in Houston, Texas, during the Society for Immunotherapy of Cancer conference. The poster details optimal dose estimation using an integrated approach from Phase 1 data and will be available on I-Mab's website under the 'Innovation, Publications & Presentations' section.

I-Mab (NASDAQ: IMAB) ha annunciato che presenterà i dati di stima della dose ottimizzata della Fase 1 per givastomig (TJ033721/ABL111) al SITC 2024. La presentazione si concentra su questo nuovo anticorpo bispecifico di prima classe per il trattamento del cancro, targeting Claudin18.2 e 4-1BB. La presentazione poster, con numero 1474, si terrà il 9 novembre 2024 presso il George R. Brown Convention Center di Houston, Texas, durante la conferenza della Society for Immunotherapy of Cancer. Il poster fornisce dettagli sull'estimazione della dose ottimale utilizzando un approccio integrato basato sui dati della Fase 1 e sarà disponibile sul sito web di I-Mab nella sezione 'Innovazione, Pubblicazioni e Presentazioni'.

I-Mab (NASDAQ: IMAB) anunció que presentará datos de estimación de dosis optimizada de la Fase 1 para givastomig (TJ033721/ABL111) en el SITC 2024. La presentación se centra en este novedoso anticuerpo bispecífico de primera clase dirigido a Claudin18.2 y 4-1BB para el tratamiento del cáncer. La presentación del póster, numerada 1474, tendrá lugar el 9 de noviembre de 2024 en el George R. Brown Convention Center en Houston, Texas, durante la conferencia de la Society for Immunotherapy of Cancer. El póster detalla la estimación de la dosis óptima utilizando un enfoque integrado a partir de los datos de la Fase 1 y estará disponible en el sitio web de I-Mab en la sección 'Innovación, Publicaciones y Presentaciones'.

I-Mab (NASDAQ: IMAB)는 SITC 2024에서 givastomig (TJ033721/ABL111)의 1상 최적 용량 추정 데이터를 발표할 것이라고 발표했습니다. 이 발표는 암 치료를 위한 혁신적인 1세대 Claudin18.2 및 4-1BB 이중 특이성 항체에 초점을 맞추고 있습니다. 포스터 발표 번호 1474는 2024년 11월 9일 텍사스 휴스턴의 George R. Brown Convention Center에서 진행되는 암 면역치료학회(Society for Immunotherapy of Cancer) 기간 중에 열립니다. 포스터에는 1상 데이터에서 통합된 접근 방식을 사용하여 최적 용량 추정에 대한 세부 정보가 포함되어 있으며, I-Mab의 웹사이트 '혁신, 출판 및 발표' 섹션에서 확인할 수 있습니다.

I-Mab (NASDAQ: IMAB) a annoncé qu'il présentera des données d'estimation de dose optimisée de la Phase 1 pour givastomig (TJ033721/ABL111) au SITC 2024. La présentation se concentre sur cet anticorps bispécifique innovant de première classe ciblant Claudin18.2 et 4-1BB pour le traitement du cancer. La présentation de l'affiche, numérotée 1474, aura lieu le 9 novembre 2024 au George R. Brown Convention Center à Houston, Texas, pendant la conférence de la Society for Immunotherapy of Cancer. L'affiche fournit des détails sur l'estimation de la dose optimale à l'aide d'une approche intégrée basée sur les données de la Phase 1 et sera disponible sur le site Web d'I-Mab dans la section 'Innovation, Publications & Présentations'.

I-Mab (NASDAQ: IMAB) hat angekündigt, dass es auf dem SITC 2024 Daten zur optimierten Dosisabschätzung in Phase 1 für givastomig (TJ033721/ABL111) präsentieren wird. Die Präsentation konzentriert sich auf diesen neuartigen bispezifischen Antikörper der ersten Klasse, der Claudin18.2 und 4-1BB für die Krebsbehandlung anvisiert. Die Posterpräsentation mit der Nummer 1474 findet am 9. November 2024 im George R. Brown Convention Center in Houston, Texas, während der Konferenz der Society for Immunotherapy of Cancer statt. Das Poster enthält Details zur optimalen Dosisabschätzung mithilfe eines integrierten Ansatzes basierend auf den Daten der Phase 1 und wird auf der Website von I-Mab im Abschnitt 'Innovation, Publikationen & Präsentationen' verfügbar sein.

Positive
  • Phase 1 dose estimation data ready for presentation, indicating progress in clinical development
  • Development of a first-in-class bispecific antibody showing potential innovation in cancer treatment
Negative
  • None.

Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024

ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody, at SITC 2024. The conference is being held in Houston, Texas, from November 6-10, 2024.

Presentation Details:

  • Title: Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody
  • Poster #: 1474
  • Presenter: J.A. Yanez, I-Mab
  • Session: Poster Hall, George R. Brown Convention Center
  • Session Date: Saturday, November 9, 2024
  • Session Time: 9:00 am CDT to 8:30 pm CDT, Level 1 – Exhibit Halls AB

A full copy of the poster will be available on the I-Mab website under the "Innovation, Publications & Presentations" tab on November 9, 2024.

About Givastomig

Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin (CLDN) 18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig appears to maintain strong tumor binding and anti-tumor activity, attributable to a synergistic effect of proximal interaction with CLDN18.2 and 4-1BB, while minimizing liver toxicity and systemic immunotoxicity commonly seen with other emerging 4-1BB-based product candidates. In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for givastomig for the treatment of gastric cancer, including cancer of the gastroesophageal junction. A Phase 1b study is ongoing evaluating givastomig, in combination with standard-of-care nivolumab plus chemotherapy, in treatment-naïve patients with gastric cancers, including gastroesophageal cancer (NCT04900818).

The program is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding China and South Korea, equally with ABL Bio.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Investor & Media Contacts

Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-present-givastomig-phase-1-optimal-dose-estimation-data-at-sitc-2024-302290887.html

SOURCE I-Mab Biopharma

FAQ

What will I-Mab (IMAB) present at SITC 2024?

I-Mab will present Phase 1 optimized dose estimation data for givastomig (TJ033721/ABL111), their novel Claudin18.2 and 4-1BB bispecific antibody, at SITC 2024 on November 9, 2024.

When and where will I-Mab (IMAB) present their givastomig data?

The presentation will take place on Saturday, November 9, 2024, from 9:00 am to 8:30 pm CDT at the George R. Brown Convention Center in Houston, Texas, during SITC 2024.

What is givastomig and what makes it unique for I-Mab (IMAB)?

Givastomig (TJ033721/ABL111) is a novel first-in-class Claudin18.2 and 4-1BB bispecific antibody developed by I-Mab for cancer treatment.

I-MAB American Depositary Shares

NASDAQ:IMAB

IMAB Rankings

IMAB Latest News

IMAB Stock Data

78.05M
62.25M
11.16%
30.88%
0.76%
Biotechnology
Healthcare
Link
United States of America
Rockville